Clinical trials: Cancer, Gastrointestinal
- Condition Cancer, Gastrointestinal
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
GIST
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
The purpose of this study is to evaluate the efficacy and safety of ponatinib in participants with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure of prior tyrosine kinase inhibitor (TKI)…
- Trial name
- GIST (NCT01874665)
- Testing
- Ponatinib
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ariad Pharmaceuticals
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT04401800
- Testing
- Lenvatinib, Tislelizumab
- Where
- 9 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Carcinoma, Hepatocellular
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
This is a Phase IIIb, one arm, multicenter, open-label study primarily designed to evaluate the safety of atezolizumab + bevacizumab in participants with unresectable or unsuitable for locoregional treatments for metastatic HCC…
- Trial name
- NCT04732286
- Testing
- Atezolizumab, Bevacizumab
- Where
- 25 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Hepatocellular
c-Met Second-Line Hepatocellular Carcinoma
This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A…
- Trial name
- NCT02115373
- Testing
- Tepotinib
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Metastatic Pancreatic Cancer
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
- Trial name
- KEYNOTE144 (NCT02362048)
- Testing
- ACP-196, ACP-196 in combination with pembrolizumab
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Acerta Pharma BV
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Pancreatic Cancer
Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer
Phase 2 Clinical trial to Evaluate the efficacy and safety of activated T-lymphocyte ("Immuncell-LC") cell therapy in Gemcitabine refractory advanced pancreatic cancer
- Trial name
- NCT00965718
- Testing
- Activated T lymphocyte
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- GC Cell Corporation
Carcinoma, Hepatocellular
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
- Trial name
- NCT03289533
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Pfizer
Fungal Infection, Acute Myelogenous Leukemia
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
The purpose of this study is: to explore the potential for different dosing strategies of posaconazole oral suspension (POS) to increase plasma levels and to profile the pharmacokinetics of these dosing strategies in patients…
- Conditions
- Fungal Infection, Acute Myelogenous Leukemia, Neutropenia
- Trial name
- NCT00686543
- Testing
- Posaconazole
- Volunteers
- 75 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastro-oesophageal Junction Cancer, Gastric Cancer
Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer
The purpose of this study is to assess the efficacy, safety and tolerability of AZD4547 compared with paclitaxel in patients with advanced gastric or lower-oesophageal cancer whose tumours are found to have FGFR2 polysomy or gene…
- Trial name
- SHINE (NCT01457846)
- Testing
- AZD4547, paclitaxel
- Where
- 61 sites in Belgium, Bulgaria and 14 more
- Volunteers
- 960 people
- Sponsor
- AstraZeneca
Gastric Cancer, Cancer of the Stomach
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic…
- Conditions
- Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction
- Trial name
- NCT03662659
- Testing
- BMS-986213, Nivolumab, XELOX
- Where
- 79 sites in United States, Argentina and 15 more
- Volunteers
- 274 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.
- Trial name
- NCT01032291
- Testing
- cetuximab, lenalidomide
- Where
- 17 sites in Australia, Belgium and 4 more
- Volunteers
- 51 people
- Sponsor
- Celgene Corporation
Colorectal Cancer
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with…
- Trial name
- NCT05824559
- Testing
- ME-344, Bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- MEI Pharma, Inc.
Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
- Conditions
- Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms
- Trial name
- NCT02834780
- Testing
- H3B-6527
- Where
- 44 sites in United States, Belgium and 9 more
- Volunteers
- 128 people
- Sponsor
- H3 Biomedicine Inc.
Gastrointestinal Stromal Tumors
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent…
- Trial name
- NCT04282980
- Testing
- DCC-2618
- Where
- 9 sites in China
- Volunteers
- 39 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Drug Interaction Potential
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
This study has two parts. Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.
- Trial name
- NCT03291288
- Testing
- Tolbutamide, Midazolam, Pexidartinib
- Where
- 11 sites in United States, Netherlands and 2 more
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Pancreatic Cancer
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
This trial will include 2 portions (phase 1 and phase 2). The first portion will be a Phase I, open label, dose escalation study to establish the maximum tolerated dose (MTD) of XB2001 as measured by Dose-Limiting Toxicity (DLT)…
- Trial name
- 1-BETTER (NCT04825288)
- Testing
- Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg
- Where
- 30 sites in United States
- Volunteers
- 76 people
- Sponsor
- XBiotech, Inc.
Stomach Neoplasms
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not…
- Trial name
- NCT00555620
- Testing
- capecitabine, oxaliplatin, sunitinib malate
- Where
- 3 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Pfizer
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
This study will evaluate the efficacy and safety of Herceptin in patients with metastatic or advanced gastric cancer with disease progression during platinum-based or 5-fluoropyrimidine-based chemotherapy.
- Trial name
- NCT02005484
- Testing
- Trastuzumab
- Where
- 12 sites in Austria, Germany
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche